About CareDX
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine company specialising in transplant diagnostics. Focused exclusively on the end-to-end transplant patient journey (pre- and post-transplant), CareDx delivers advanced diagnostic solutions, software analytics, and data-driven insights designed to improve patient outcomes and extend graft survival.
At DKSH Australia, our specialist Clinical Diagnostics team partners with CareDx to support the distribution, implementation, and market expansion of these transformative technologies across Australia and New Zealand. We work closely with laboratories and clinicians to introduce innovative diagnostic assays that enhance workflow efficiency, improve reporting capabilities, and deliver greater analytical sensitivity.
CareDx has conducted landmark studies in transplant monitoring and surveillance, establishing strong clinical evidence for the use of next-generation sequencing (NGS)-based solutions in transplant care.
Comprehensive Transplant Testing Portfolio
The AlloSeq™ and QTYPE™ portfolio supports both pre- and post-transplant applications:
Pre-Transplant Solutions
- QTYPE™ Real-Time HLA Typing
High-resolution typing with enhanced single antigen bead resolution for improved donor-recipient matching
| Features: |
Benefits: |
- High-resolution typing capability
- Enhanced single antigen bead resolution
- Real-time PCR-based HLA typing
|
- Improved matching accuracy, reducing risk of transplant complications
- Greater specificity in antibody detection and compatibility assessment
- Rapid turnaround time for donor-recipient matching decisions
|
- AlloSeq™ Tx HLA Typing
NGS-based typing solutions enabling accurate and scalable transplant preparation workflows
| Features: |
Benefits: |
- Comprehensive HLA gene coverage
- High accuracy and reproducibility
- Next-generation sequencing (NGS) technology
|
- Increased confidence in donor-recipient compatibility assessment
- Reliable results supporting clinical decision-making
- High-throughput, scalable testing for busy transplant centres
|
Post-Transplant Monitoring
- AlloSeq™ HCT (Chimerism Testing)
Enables monitoring of engraftment and donor cell dynamics following transplantation
| Features: |
Benefits: |
- High sensitivity and precision
- Software analysis – surveillance monitoring and reporting
- NGS-based chimerism analysis
|
- Early detection of relapse or graft failure
- Enables longitudinal tracking of engraftment status
- Sensitive detection of donor vs recipient DNA post-transplant
|
- AlloSeq™ cfDNA (dd-cfDNA Testing)
Non-invasive monitoring of graft health in solid organ transplant recipients through donor-derived cell-free DNA
| Features: |
Benefits: |
- Measurement of donor-derived cell-free DNA (dd-cfDNA)
- Early detection of graft injury across solid organ transplants
- Reduces reliance on invasive biopsies
|
- Non-invasive assessment of graft injury or rejection risk
- Enables proactive clinical intervention and improved patient outcomes
- Improved patient experience and reduced procedural risk
|
Regulatory & Service Capabilities
All CareDx products are CE marked or available for Research Use Only (RUO) in accordance with local regulatory requirements.
Partner with DKSH New Zealand
Engage with DKSH New Zealand's Clinical Diagnostics specialists to explore how CareDx solutions can be implemented within your laboratory.
We provide:
- Product demonstrations and application support
- Workflow optimisation guidance
- Market-leading diagnostic technologies aligned with clinical demand
Discover how CareDx and DKSH New Zealand can support your transplant diagnostics strategy.
